SG11201810210UA - Engineered botulinum neurotoxins - Google Patents

Engineered botulinum neurotoxins

Info

Publication number
SG11201810210UA
SG11201810210UA SG11201810210UA SG11201810210UA SG11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA SG 11201810210U A SG11201810210U A SG 11201810210UA
Authority
SG
Singapore
Prior art keywords
international
boston
pct
disclosed
substitution mutations
Prior art date
Application number
SG11201810210UA
Inventor
Sicai Zhang
Min Dong
Paul Stenmark
Original Assignee
Childrens Medical Center
Paul Stenmark
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center, Paul Stenmark filed Critical Childrens Medical Center
Publication of SG11201810210UA publication Critical patent/SG11201810210UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111111111111111111111111111111111111111111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/214447 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: (74) Agent: EL-HAYEK, Roque; Wo1f, Greenfield & Sacks, C07K 14/33 (2006.01) A61K 38/48 (2006.01) P.c., 600 Atlantic Avenue, Boston, MA 02210-2206 (US). A61K 38/00 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: PCT/US2017/036628 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (22) International Filing Date: 08 June 2017 (08.06.2017) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (25) Filing Language: English KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (26) Publication Language: English MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (30) Priority Data: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 62/347,579 08 June 2016 (08.06.2016) US TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant. CHILDREN'S MEDICAL CENTER COR- (84) Designated States (unless otherwise indicated, for every PORATION [US/US]; 55 Shattuck Street, Boston, MA kind of regional protection available): ARIPO (BW, GH, 02115 (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (72) Inventor; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: STENMARK, Paul [SE/SE]; Svantearrhenius- EE, ES, FL FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, — vag 16c, 10691 Stockholm (SE). MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Inventors: ZHANG, Sicai; En 1070, 300 Longwood Ave, (72) TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = Boston, MA (US). DONG, Min; 12 Croft Lane, Weatogue, CT 06089 (US). KM, ML, MR, NE, SN, TD, TG). = Title: ENGINEERED BOTULINUM NEUROTOXINS (54) = (57) : Disclosed herein are modified Clostridial Botulinum neurotoxin (BoNT) polypep- 3 tides with a modified receptor binding domain of Clostridial Botulinum serotype B, compris- = — ing one or more substitution mutations at positions corresponding 1248 or 1249 in serotype B, Z strain 1. Specific substitution mutations include I1248F, I1248Y, I1248H, I1248W, V1249W, = g g. V1249F, V1249Y, V1249H, I1248WN1249F, I1248WN1249Y, I1248WN1249H, I1248F/ = = = 1 V1249Y, I1248FN1249H, I1248YN1249H, I1248F/V1249W, I1248YN1249W, I1248H/ bind i V 1249W, I1248Y/V1249F, I1248H/V1249F, or I1248HN1249Y. Other substitution mutations are = = also disclosed. Isolated modified receptor binding domains, chimeric molecules, pharmaceutical _ total compositions, and methods of using the same are also disclosed. = ..... actin = = FIG. 4A 4 = — = 2 1 — Il Ir ... ' Il ei 4. 1' ‘., IN 4B FIG. P S I ei C [Continued on next page] WO 2017/214447 Al MIDEDIMOMMIDIRMEM001101011101110HOHNEVOIMIE Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event amendments (Rule 48.2(h)) of receipt of
SG11201810210UA 2016-06-08 2017-06-08 Engineered botulinum neurotoxins SG11201810210UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662347579P 2016-06-08 2016-06-08
PCT/US2017/036628 WO2017214447A1 (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins

Publications (1)

Publication Number Publication Date
SG11201810210UA true SG11201810210UA (en) 2018-12-28

Family

ID=59227906

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201810210UA SG11201810210UA (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins
SG10201912099TA SG10201912099TA (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201912099TA SG10201912099TA (en) 2016-06-08 2017-06-08 Engineered botulinum neurotoxins

Country Status (13)

Country Link
US (1) US11104891B2 (en)
EP (1) EP3468985A1 (en)
JP (2) JP7152392B2 (en)
KR (1) KR20190025906A (en)
CN (1) CN109476713A (en)
AU (1) AU2017277905B2 (en)
BR (1) BR112018075363A2 (en)
CA (1) CA3026492A1 (en)
EA (1) EA201892784A1 (en)
IL (1) IL263058B2 (en)
MX (1) MX2018015254A (en)
SG (2) SG11201810210UA (en)
WO (1) WO2017214447A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201407784UA (en) 2012-05-30 2014-12-30 Harvard College Engineered botulinum neurotoxin
EP3274364B1 (en) * 2015-03-26 2021-08-04 President and Fellows of Harvard College Engineered botulinum neurotoxin
TW201718627A (en) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 Recombinant clostridial neurotoxin, a use thereof, and a method for generating the same, a pharmaceutical composition comprising the same and a precursor corresponding to the same, a nucleic acid sequence encoding the precursor and a method for obtaining
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
UA127310C2 (en) * 2016-05-16 2023-07-19 Презідент Енд Феллоуз Оф Гарвард Колледж Method for purification and activation of botulinum neurotoxin
EA201990229A1 (en) * 2016-07-08 2019-06-28 Пол Стенмарк NEW BOTULINIC NEUROTOXIN AND ITS DERIVATIVES
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
TWI810228B (en) * 2017-12-20 2023-08-01 英商艾普森生物製藥有限公司 Treatment of autonomic disorders
JP2021517825A (en) * 2018-01-30 2021-07-29 チルドレンズ メディカル センター コーポレーションＣｈｉｌｄｒｅｎ’Ｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Ｃｏｒｐｏｒａｔｉｏｎ Production of botulinum toxin using the BACILLUS system
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
SE542539C2 (en) * 2018-02-26 2020-06-02 Toxotech Ab Chimeric botulinum neurotoxin heavy chain binding domain
CN114957482A (en) * 2021-02-26 2022-08-30 重庆誉颜制药有限公司 Modified single-chain polypeptide of neurotoxin and application thereof
KR20230001254A (en) 2021-06-28 2023-01-04 (주)메디톡스 Recombinant botulinum toxin type A light chain, recombinant botulinum toxin, and its compositions, uses and methods
KR20230001260A (en) 2021-06-28 2023-01-04 (주)메디톡스 Recombinant botulinum toxin type A light chain, recombinant botulinum toxin, and its compositions, uses and methods
WO2023068485A1 (en) * 2021-10-22 2023-04-27 비피메드(주) Composition for ameliorating hair loss comprising botulinum-derived peptide
CA3234608A1 (en) * 2021-11-22 2023-05-25 Ipsen Biopharm Limited Treatment of pain
CN114369623B (en) * 2022-01-12 2023-07-07 中国人民解放军空军军医大学 Syntagmin 2-RNAi based on Cre-lox recombination system and application thereof
CN114410683B (en) * 2022-01-12 2023-11-28 中国人民解放军空军军医大学 RIM3-RNAi based on Cre-lox recombination system and application thereof
GB202206348D0 (en) * 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
WO2024080682A1 (en) * 2022-10-12 2024-04-18 주식회사 알케미어 Light chain mutant of botulinum toxin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (en) 1987-02-09 1996-03-13 株式会社ビタミン研究所 Antitumor agent-embedded liposome preparation
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
JP3066079B2 (en) 1994-05-09 2000-07-17 ビンダー，ウィリアム，ジェイ． How to reduce headaches
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
DE102005019302A1 (en) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier for targeting nerve cells
CN102796743B (en) * 2006-01-13 2015-11-18 美国政府健康及人类服务部国立卫生研究院 For codon optimized IL-15 and the IL-15R α gene of expressing in mammalian cell
US8273865B2 (en) 2006-03-15 2012-09-25 Allergan, Inc. Multivalent clostridial toxins
SG11201407784UA (en) * 2012-05-30 2014-12-30 Harvard College Engineered botulinum neurotoxin
CN107624115B (en) 2015-03-16 2021-10-26 加州理工学院 Botulinum neurotoxin specific capture agents, compositions, methods of use, and methods of manufacture
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins

Also Published As

Publication number Publication date
WO2017214447A1 (en) 2017-12-14
AU2017277905B2 (en) 2022-04-14
JP7152392B2 (en) 2022-10-12
JP2019523015A (en) 2019-08-22
CN109476713A (en) 2019-03-15
CA3026492A1 (en) 2017-12-14
US20190300869A1 (en) 2019-10-03
AU2017277905A1 (en) 2018-12-20
US11104891B2 (en) 2021-08-31
IL263058A (en) 2018-12-31
EA201892784A1 (en) 2019-05-31
MX2018015254A (en) 2019-08-16
IL263058B2 (en) 2023-11-01
SG10201912099TA (en) 2020-02-27
IL263058B1 (en) 2023-07-01
BR112018075363A2 (en) 2019-03-19
KR20190025906A (en) 2019-03-12
EP3468985A1 (en) 2019-04-17
JP2022112031A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
SG11201810210UA (en) Engineered botulinum neurotoxins
SG11201811338VA (en) A novel botulinum neurotoxin and its derivatives
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201903089RA (en) Aav delivery of nucleobase editors
SG11201901941YA (en) High purity rna compositions and methods for preparation thereof
SG11201809559UA (en) Substituted pyridines as inhibitors of dnmt1
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201407784UA (en) Engineered botulinum neurotoxin
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201909837YA (en) Methods for treating lung disorders
SG11201903230QA (en) TCRa HOMING ENDONUCLEASE VARIANTS
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201804856VA (en) C-terminal lysine conjugated immunoglobulins
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201809903WA (en) Method for purification and activation of botulinum neurotoxin